Latest Commercialization News

Carnaby Resources has extended its high-grade Trek 1 Footwall Lode at the Greater Duchess Project, delivering a 38m intercept at 1.9% copper equivalent and keeping the discovery wide open for further growth.

AFT Pharmaceuticals posted a 22% revenue jump to NZ$254.7 million and a 39% increase in operating profit to a record NZ$24.4 million for FY26, exceeding guidance. The company targets over NZ$300 million revenue for FY27, fueled by international expansion and a deepening R&D pipeline.

TruScreen Group Limited has kicked off a NZ$2.9 million capital raising combining a NZ$1 million placement and a NZ$1.94 million rights issue to fund its global expansion and regulatory compliance efforts. The company reported a 42% jump in product sales for FY2026 and is targeting major public health programs across 14 countries.

Turners Automotive Group has posted a record $63.2 million normalised NPBT for FY26, advancing its $65 million NPBT target to FY27 and setting sights on $100 million by FY31 amid solid finance and retail momentum.

BLIS Technologies posted a 16% revenue increase to $14.7 million in FY26, resolving a key intellectual property dispute and expanding strategic partnerships, including an extended Probi AB agreement that now covers pet nutrition.

Helios Energy Ltd has secured $1.51 million through a share placement priced at $0.003 each, while extinguishing $100,000 of convertible note debt by issuing shares to noteholders. The capital boost aims to support working capital as the company advances its Texas oil projects.

Gold Hydrogen is accelerating Helium development at its Ramsay Project, leveraging exceptional purity results and independent modelling amid a tightening global Helium supply.

RAS Technology Holdings has locked in new contracts and extensions expected to add at least $2 million in annualised revenue, reinforcing growth in wagering technology and international markets.

Mach7 Technologies has secured a five-year, A$1.7 million subscription contract with US teleradiology provider AMRADNET, slashing deployment time from 12 months to just 45 days.

Cleo Diagnostics has laid out a clear U.S. reimbursement pathway for its ovarian cancer test, leveraging an existing CPT code to enable early market entry and data collection ahead of FDA clearance.

EBR Systems has locked in a three-year purchasing agreement with CHRISTUS Health, the ninth-largest US hospital network, to advance its WiSE CRT System's US rollout across 66 hospitals.

OncoSil Medical has clinched TGA approval for its OncoSil™ device, the first Class III medical device targeting pancreatic tumours in Australia, paving the way for local commercialisation and enhanced patient access.